SCHEMBL24722182

SCHEMBL24722182

CC(=O)C(C)CCCCCCN1C(=O)C=CC1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 7/20 0.57
▸ FAAH O00519 5/20 0.57
▸ LMNA P02545 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ HSP90AA1 P07900 1/20 0.57
▸ TLR9 Q9NR96 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ TP53 P04637 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ PKM P14618 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ XBP1 P17861 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ HTT P42858 1/20 0.57
▸ RECQL P46063 1/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ GPR35 Q9HC97 1/20 0.57
▸ GPR55 Q9Y2T6 1/20 0.57
▸ PTGS1 P23219 7/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23506616 0.86 MGLL (0.45) MGLLFAAHLMNASMN1; SMN2HSP90AA1
SCHEMBL28168582 0.85 MGLL (0.55) MGLLFAAHLMNASMN1; SMN2HSP90AA1
SCHEMBL3646854 0.83 MGLL (0.53) MGLLFAAHLMNASMN1; SMN2HSP90AA1
SCHEMBL17453149 0.82 PTGS1 (0.39) MGLLFAAHLMNASMN1; SMN2HSP90AA1
SCHEMBL25148203 0.81 MGLL (0.63) MGLLFAAHLMNASMN1; SMN2HSP90AA1
SCHEMBL14962677 0.80 MGLL (0.68) MGLLFAAHLMNASMN1; SMN2HSP90AA1
SCHEMBL13078197 0.80 MGLL (0.68) MGLLFAAHLMNASMN1; SMN2HSP90AA1
SCHEMBL14868075 0.80 MGLL (0.68) MGLLFAAHLMNASMN1; SMN2HSP90AA1
SCHEMBL14868080 0.80 MGLL (0.68) MGLLFAAHLMNASMN1; SMN2HSP90AA1
SCHEMBL18942765 0.80 MGLL (0.53) MGLLFAAHLMNASMN1; SMN2HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259225-A1 Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use REGENERON PHARMACEUTICALS, INC. 2022-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259225-A1 Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use SLC10A1, HNMT, OGFR MGLL 4069/4885FAAH 2211/4885LMNA 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback